NCT06790420View on ClinicalTrials.gov

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
Lymphoma
Interventions
DRUG

Rituximab Pfizer

For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times

DRUG

Rituxan

For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times

Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06790420 - RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study | Biotech Hunter | Biotech Hunter